NIH StatPearls: Kratom Pharmacology, Toxicology, and Clinical Management—An Evidence-Based Overview

Why it matters

This continually updated NIH reference serves as the primary clinical guide used by emergency physicians, pharmacists, and nurses treating kratom toxicity—making its evidence summary critical for frontline care.

The big picture

As kratom use increases in the U.S., emergency department visits and poison center calls related to kratom have risen sharply. Clinicians often lack specific guidelines for treating kratom toxicity, and this NIH resource helps bridge that gap by synthesizing pharmacological data and case-based clinical evidence for an interprofessional audience.

Key findings

• 7-OH-mitragynine is approximately 13 times more potent than morphine at opioid receptors and 46 times more potent than mitragynine.
• Kratom alkaloids activate G-protein-coupled receptors but do not recruit the beta-arrestin pathway, which is responsible for respiratory depression and other opioid side effects.
• Toxicities typically occur when ingested dose exceeds 8 grams; stimulant effects occur at low doses, opioid-like effects at high doses.
• Kratom does not appear on standard drug screens, complicating clinical identification.
• No evidence-based treatment guidelines exist; naloxone may partially reverse opioid-like toxicity; N-acetylcysteine has been used for drug-induced hepatitis cases.
• Multiple organ systems are at risk: hepatotoxicity, seizures, lung injury, kidney injury, and cardiotoxicity documented in case studies.

What they say

"Given the current opioid epidemic, physicians are encouraged to avoid overprescribing opioids for pain management. However, patients who develop opioid dependence may resort to alternatives, like kratom, as their opioid prescriptions become more difficult to obtain," according to the StatPearls authors Ivanov and Pippin.

Bottom line

**Kratom's active metabolite 7-OH-mitragynine is far more potent than morphine, does not appear on standard drug screens, and has no established evidence-based treatment protocol—making clinical awareness and interprofessional coordination essential for managing toxicity.**